CERo Therapeutics Holdings, Inc.
CERO
$0.09
$0.0113.64%
OTC PK
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 0.22% | 41.99% | 56.67% | 136.16% | 126.46% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 14.93% | 37.86% | 74.10% | 115.72% | 98.35% |
| Operating Income | -14.93% | -37.86% | -74.10% | -115.72% | -98.35% |
| Income Before Tax | -43.61% | -91.22% | -58.57% | -16.22% | -82.75% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -43.61% | -91.22% | -58.57% | -16.22% | -66.73% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -43.61% | -91.22% | -58.57% | -16.22% | -66.73% |
| EBIT | -14.93% | -37.86% | -74.10% | -115.72% | -98.35% |
| EBITDA | -16.37% | -40.18% | -78.44% | -123.60% | -144.43% |
| EPS Basic | 53.01% | -95.73% | -160.72% | -323.65% | -183.72% |
| Normalized Basic EPS | 61.63% | -280.51% | -264.12% | -- | -299.85% |
| EPS Diluted | 53.01% | -95.73% | -160.72% | -323.65% | -183.72% |
| Normalized Diluted EPS | 61.63% | -280.51% | -264.12% | -- | -299.85% |
| Average Basic Shares Outstanding | 10,517.07% | 14,192.35% | 12,904.49% | -- | -71.60% |
| Average Diluted Shares Outstanding | 6,517.20% | 1,726.30% | 935.79% | 112.18% | -88.61% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |